Los Altos, California, October 28, 2025 — Unicycive Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for kidney disease, announced an update from its Type A meeting with the U.S. Food and Drug Administration (FDA) regarding the resubmission of its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC). Following the meeting, the company confirmed plans to resubmit the NDA before the end of 2025, aiming for a potential Prescription Drug User Fee Act (PDUFA) date in the first half of 2026. The FDA’s previous Complete Response Letter (CRL) identified a single manufacturing-related deficiency, now expected to be resolved after collaborative discussions with a third-party vendor. With a cash runway extending into 2027, Unicycive is financially positioned to support resubmission, potential FDA approval, and commercial launch of OLC.
Science Significance
Oxylanthanum Carbonate (OLC) is an investigational oral phosphate binder designed to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. Utilizing proprietary nanoparticle technology, OLC delivers high phosphate-binding potency with a significantly lower pill burden, improving treatment adherence compared to existing therapies. The drug candidate’s best-in-class potential stems from its innovative design, which efficiently binds dietary phosphate in the gastrointestinal tract to reduce absorption into the bloodstream. Its development reflects cutting-edge material science and nanotechnology applied to address one of the most burdensome complications of kidney disease.
Regulatory Significance
The FDA’s Type A meeting outcome indicates a clear and constructive regulatory path forward. The single issue raised in the CRL pertained solely to manufacturing compliance at a third-party vendor, with no deficiencies found in preclinical, clinical, or safety data. This signals a favorable regulatory environment for resubmission. The company plans to refile the NDA via the 505(b)(2) regulatory pathway, which allows reliance on existing safety and efficacy data of approved compounds while introducing new formulation innovations. If resubmitted in 2025, OLC could receive approval by mid-2026, demonstrating regulatory efficiency, compliance transparency, and product quality assurance under FDA’s strict standards.
Business Significance
Advertisement
This development strengthens Unicycive Therapeutics’ position as an emerging leader in the kidney-disease market, valued at over $2 billion annually for phosphate-binding therapies. The company’s solid financial foundation, with $42 million in cash as of September 30, 2025, ensures operational continuity through regulatory milestones and pre-launch activities. An eventual approval could unlock significant commercial potential, positioning OLC as a high-value, patient-centric alternative in a market dominated by older, high-burden phosphate binders. Moreover, the NDA progress reflects investor confidence in Unicycive’s leadership, product pipeline, and regulatory acumen.
Patients’ Significance
For patients with end-stage renal disease (ESRD) undergoing dialysis, hyperphosphatemia is a persistent, life-threatening challenge that affects nearly 450,000 individuals in the United States each year. Current treatments often require large pill counts and frequent dosing, leading to poor adherence and suboptimal phosphate control. OLC’s nanoparticle-based formulation and lower pill burden directly address these issues, offering improved convenience, compliance, and quality of life. The drug’s potential to provide effective phosphate management with fewer side effects may significantly enhance long-term outcomes for patients with chronic kidney conditions.
Policy Significance
This update aligns with the FDA’s mission to accelerate patient access to safer and more effective therapies while ensuring manufacturing compliance. The resolution of the CRL demonstrates the regulatory system’s flexibility and collaboration in addressing non-clinical deficiencies, allowing innovation to advance responsibly. OLC’s pathway also reflects the importance of public health policies supporting renal care innovation, addressing the global burden of CKD, and improving access to life-sustaining therapies for dialysis patients.
Unicycive Therapeutics’ commitment to resubmitting its NDA for Oxylanthanum Carbonate exemplifies the intersection of scientific innovation, regulatory discipline, and patient-centered development. With strong FDA engagement, financial stability, and technological promise, the company is poised to advance OLC toward market readiness. The successful resolution of its manufacturing issue and an expected 2026 approval could position Unicycive as a transformative force in kidney-disease therapeutics — delivering next-generation phosphate control and better outcomes for patients worldwide.
Source: Unicycive Therapeutics, Inc. press release
